Pfizer withdraws Macugen for DMO in Europe
This article was originally published in Scrip
Executive Summary
The original victim of Lucentis' (ranibizumab) efficacy, Pfizer's Macugen, has been officially withdrawn from development in diabetic macular oedema, months after Pfizer handed back another DMO project. The move calls into question not only Pfizer's position in the indication, but also the prospects for a range of other compounds in development for DMO (Table 1)
You may also be interested in...
Stockwatch: A Biopharma Nativity Play
The cadence of the news in the biopharmaceutical space slowed significantly last week in the run-up to the holidays. In seasonal spirit, Andy “the innkeeper” Smith assigns roles in the Christmas nativity play to those who did come forward – including Ophthotech, Amicus and Lilly.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.